Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

$100K fine follows tower crane incident that caused hospital roof collapse

Nexon partners with Dementia Australia to tackle dementia stigma in the workplace

"Migrant worker exploitation" sees NSW aged care provider repay nearly $120K

A Day in the Life of a birth suite ANUM

Professor Andrea Driscoll MACN wins 2026 Nursing Trailblazers Award

From compliance to circularity: three ways pharma manufacturers can rethink resource management

Tomago Aluminium smelter gets green investment

Stantec acquires Sydney-based consultancy

Researchers recover silver from end-of-life solar panels

Soft Low-E coated photovoltaic glass reduces energy demand

From smart sensors to autonomous factories: why the next decade of AI will transform industry

Rockwell announces AI inspection technology

The accelerating decline of fieldbus as Ethernet takes over

ANSTO celebrates 20 years of OPAL supporting research and innovation

Engineers Australia marks International Youth Day

Lonza bone marrow and cord blood mononuclear cells

Antibodies Inc recombinant antibodies

Bioss Multiplex Fluorescent IHC Staining Kit

AdipoGen immune checkpoint reagents for immuno-oncology research

Content from other channels on our network